ADALAT LA 30 TABLET 30 mg

Land: Singapore

Sprog: engelsk

Kilde: HSA (Health Sciences Authority)

Aktiv bestanddel:

NIFEDIPINE

Tilgængelig fra:

BAYER (SOUTH EAST ASIA) PTE LTD

ATC-kode:

C08CA05

Dosering:

30 mg

Lægemiddelform:

TABLET, FILM COATED

Sammensætning:

NIFEDIPINE 30 mg

Indgivelsesvej:

ORAL

Recept type:

Prescription Only

Fremstillet af:

Bayer AG

Autorisation status:

ACTIVE

Autorisation dato:

1994-05-05

Indlægsseddel

 Adalat LA PI_SG_CCDS16_ 27 Jun 2012 

1 

Instructions for use 

Please read carefully! 

Active ingredient: nifedipine 
Extended release tablets 

 Coronary therapeutic/antihypertensive 
                     active ingredient nifedipine 

              Extended release tablets 

 PRESCRIPTION USE ONLY 

QUANTITATIVE COMPOSITION 

ADALAT LA 20 : 1 prolonged-release tablet contains 20
mg nifedipine  
ADALAT LA 30 : 1 prolonged-release tablet contains 30
mg nifedipine  
ADALAT LA 60 : 1 prolonged-release tablet contains 60
mg nifedipine  

PHARMACEUTICAL FORM 

Adalat LA 20: Round, convex prolonged-release tablet with
pink coat, laser hole on one side 
and ADALAT20 on the other. 
Adalat LA 30: Round, convex prolonged-release tablet with
pink coat, laser hole on one side 
and ADALAT30 on the other. 
Adalat LA 60: Round, convex prolonged-release tablet with
pink coat, laser hole on one side 
and ADALAT60 on the other. 

PHARMACODYNAMIC PROPERTIES 

Nifedipine is a calcium antagonist of the 1,4-dihydropyridine
type. Calcium antagonists reduce 
the transmembranal influx of calcium ions through the
slow calcium channel into the cell. 
Nifedipine acts particularly on the cells of the myocardium and
the smooth muscle cells of the 
coronary arteries and the peripheral resistance vessels. 

In the heart nifedipine dilates the coronary arteries, especially the
large conductance vessels, 
even in the free wall segment of partially stenosed
areas. Further, nifedipine reduces the 
vascular smooth muscle tone in the coronary arteries and
prevents vasospasm. The end-result 
is an increased poststenotic blood flow and an increased oxygen
supply. Parallel to this, 
nifedipine reduces the oxygen
requirement by lowering p

Produktets egenskaber

Adalat LA PI_CCDS17_October 2017
1
INSTRUCTIONS FOR USE
PLEASE READ CAREFULLY!
ADALAT® LA
ACTIVE INGREDIENT: NIFEDIPINE
Coronary therapeutic/antihypertensive
Extended release tablets
PRESCRIPTION USE ONLY
EXTENDED RELEASE TABLETS
ACTIVE INGREDIENT NIFEDIPINE
QUANTITATIVE COMPOSITION
ADALAT LA 20 : 1 prolonged-release tablet contains 20 mg nifedipine
ADALAT LA 30 : 1 prolonged-release tablet contains 30 mg nifedipine
ADALAT LA 60 : 1 prolonged-release tablet contains 60 mg nifedipine
PHARMACEUTICAL FORM
Adalat LA 20: Round, convex prolonged-release tablet with pink coat,
laser hole on one side
and ADALAT20 on the other.
Adalat LA 30: Round, convex prolonged-release tablet with pink coat,
laser hole on one side
and ADALAT30 on the other.
Adalat LA 60: Round, convex prolonged-release tablet with pink coat,
laser hole on one side
and ADALAT60 on the other.
PHARMACODYNAMIC PROPERTIES
Nifedipine is a calcium antagonist of the 1,4-dihydropyridine type.
Calcium antagonists reduce
the transmembranal influx of calcium ions through the slow calcium
channel into the cell.
Nifedipine acts particularly on the cells of the myocardium and the
smooth muscle cells of the
coronary arteries and the peripheral resistance vessels.
In the heart nifedipine dilates the coronary arteries, especially the
large conductance vessels,
even in the free wall segment of partially stenosed areas. Further,
nifedipine reduces the vascular
smooth muscle tone in the coronary arteries and prevents vasospasm.
The end-result is an
increased poststenotic blood flow and an increased oxygen supply.
Parallel to this, nifedipine
reduces the oxygen requirement by lowering peripheral resistance
(afterload). With long-term
use nifedipine can also prevent the development of new atherosclerotic
lesions in the coronary
arteries.
Nifedipine reduces the smooth muscle tone of the arterioles, thus
lowering the increased
peripheral resistance and consequently the blood pressure. At the
beginning of the nifedipine
treatment there may be a transient reflex increase in he